Asensus Surgical, Inc. traded at $0.27 this Tuesday April 9th, increasing $0.004 or 1.36 percent since the previous trading session. Looking back, over the last four weeks, Asensus Surgical gained 9.34 percent. Over the last 12 months, its price fell by 56.65 percent. Looking ahead, we forecast Asensus Surgical, Inc. to be priced at 0.26 by the end of this quarter and at 0.25 in one year, according to Trading Economics global macro models projections and analysts expectations.
Asensus Surgical, Inc. is a medical device company that is digitizing the interface between the surgeon and the patient through Performance-Guided Surgery. The Company is focused on the market development and commercialization of the Senhance Surgical System, which digitizes laparoscopic minimally invasive surgery (MIS). The Senhance System is a digital and multi-port laparoscopic platform designed to maintain laparoscopic MIS standards while providing digital benefits, such as haptic feedback, robotic precision, comfortable ergonomics, advanced instrumentation, including three-millimeter (mm) micro laparoscopic instruments, five mm articulating instruments, eye-sensing camera control and fully reusable standard instruments to patients around the world. Its Senhance System is used in Europe for adult and pediatric laparoscopic abdominal and pelvic surgery, as well as limited thoracic operations. It is also available in the United States, Japan, Taiwan and Russia.